Patient Name : SUDHA RANI Barcode : A0282147

Age/Gender : 52Y 0M 0D /Female Sample Collected On : 05/Dec/2024 02:53PM

Order Id : 12266358238 Sample Received On : 06/Dec/2024 09:15AM
Referred By : Self Report Generated On : 06/Dec/2024 09:55AM
Customer Since : 05/Dec/2024 Sample Temperature : Maintained
Sample Type : Whole Blood EDTA Report Status : Final Report

DEPARTMENT OF BIOCHEMISTRY HBA1C

Test Name Value Unit Bio. Ref Interval

HbA1c - Glycosylated Hemoglobin

Hba1c (Glycosylated Hemoglobin) 6.60 % 4.2 - 5.7
Method: HPLC
Machine: TOSOH G11
Average Estimated Glucose - plasma 142.72 mg/dl
Method: Calculated
INTERPRETATION:
AS PER AMERICAN DIABETES ASSOCIATION (ADA):
REFERENCE GROUP GLYCOSYLATED HEMOGLOBIN (HBA1c) in %
Non diabetic <5.7
At Risk (Prediabetes) 5.7 – 6.4
Diagnosing Diabetes >= 6.5
Age > 19 Years
Goals of Therapy: < 7.0
Actions Suggested: >8.0
Therapeutic goals for glycemic control Age < 19 Years
Goal of therapy: <7.5

REMARKS

1. HbA1c is used for monitoring diabetic control. It reflects the mean plasma glucose over three months
2. HbA1c may be falsely low in diabetics with hemolytic disease. In these individuals a plasma fructosamine level may be used which evaluates diabetes over 15
days.
3. Inappropriately low HbA1c values may be reported due to hemolysis, recent blood transfusion, acute blood loss, hypertriglyceridemia, chronic liver disease.
Drugs like dapsone, ribavirin, antiretroviral drugs, trimethoprim, may also cause interference with estimation of HbA1c, causing falsely low values.
4. HbA1c may be increased in patients with polycythemia or post-splenectomy.
5. Inappropriately higher values of HbA1c may be caused due to iron deficiency, vitamin B12 deficiency, alcohol intake, uremia, hyperbilirubinemia and large doses
of aspirin.
6. Trends in HbA1c are a better indicator of diabetic control than a solitary test. 7. Any sample with >15% HbA1c should be suspected of having a hemoglobin
variant, especially in a non-diabetic patient. Similarly, below 4% should prompt additional studies to determine the possible presence of variant hemoglobin.
8. HbA1c target in pregnancy is to attain level <6 % .
9. HbA1c target in paediatric age group is to attain level < 7.5 %.
Method : Ion-exchange high-performance liquid chromatography (HPLC).
Reference : American Diabetes Associations. Standards of Medical Care in Diabetes 2023
10.The presence of some hemoglobinopathies/hemoglobin variants may be missed by some platforms used for measuring HbA1c values. In these cases, the
HbA1c result may vary or give deviant results, depending on the platform used. Alternative measures of glycemic control like fructosamine or glycated albumin
may be considered in such cases.
11.In presence of hemoglobinopathy/hemoglobin variants in homozygous/compound heterozygous conditions alternative forms of testing such as fructosamine or
glycated albumin may be considered.

Page 1 of 5

SIN No:A0282147
 Patient Name : SUDHA RANI Barcode : A0282147
Age/Gender : 52Y 0M 0D /Female Sample Collected On : 05/Dec/2024 02:53PM
Order Id : 12266358238 Sample Received On : 06/Dec/2024 09:15AM
Referred By : Self Report Generated On : 06/Dec/2024 02:29PM
Customer Since : 05/Dec/2024 Sample Temperature : Maintained
Sample Type : Whole Blood EDTA Report Status : Final Report

DEPARTMENT OF HAEMATOLOGY-HPLC

Test Name Value Unit Bio. Ref Interval

ABNORMAL HB STUDIES (HB ELECTROPHORESIS)

HEMATOLOGICAL PARAMETERS
Haemoglobin (HB) 10.8 g/dL 12.0-15.0
Method: Photometry
Machine: BECKMAN COULTER DxH900
Hematocrit (PCV) 33.6 % 36.0-46.0
Method: Calculated
Machine: BECKMAN COULTER DxH900
Red Blood Cell Count (RBC) 4.50 10^6/µl 3.80-4.80
Method: Impedance
Machine: BECKMAN COULTER DxH900
Mean Corp Volume (MCV) 74.6 fL 83.0-101.0
Method: Derived from RBC Histogram
Machine: BECKMAN COULTER DxH900
Mean Corp Hb (MCH) 24 pg 27.0-32.0
Method: Calculated
Machine: BECKMAN COULTER DxH900
Mean Corp Hb Conc (MCHC) 32.2 g/dL 31.5-34.5
Method: Calculated
Machine: BECKMAN COULTER DxH900
RDW - CV 18.8 % 11.6-14.0
Method: Derived from RBC Histogram
Machine: BECKMAN COULTER DxH900
RDW - SD 49.90 fL 39.0-46.0
Method: Derived from RBC Histogram
Machine: BECKMAN COULTER DxH900
ABNORMAL HB STUDIES (HB ELECTROPHORESIS)
HEMOGLOBIN A (Hb Adult) 97.2 % 95.8 - 97.8
Method: HPLC
HEMOGLOBIN A2 (HbA2) 2.4 % 2.0 - 3.5
Method: HPLC
FETAL HEMOGLOBIN (Hb F) 0.3 % 0.0 - 2.0
Method: HPLC

Page 2 of 5

SIN No:A0282147
 Patient Name : SUDHA RANI Barcode : A0282147
Age/Gender : 52Y 0M 0D /Female Sample Collected On : 05/Dec/2024 02:53PM
Order Id : 12266358238 Sample Received On : 06/Dec/2024 09:15AM
Referred By : Self Report Generated On : 06/Dec/2024 02:29PM
Customer Since : 05/Dec/2024 Sample Temperature : Maintained
Sample Type : Whole Blood EDTA Report Status : Final Report

DEPARTMENT OF HAEMATOLOGY-HPLC

Test Name Value Unit Bio. Ref Interval

Suggestive Interpretation NORMAL HB

CHROMATOGRAPHY
ANALYSIS. NO
HAEMOGLOBINOPATHY IS
DETECTED.
Test Interpretation
Method: High Performance Llquid Chromatography (HPLC).

Note:
• Determinaton of elevated levels of hemoglobin HB A2 & F is the most practical means of diagnosing inheritance of beta-thalassemia gene .
• HPLC is a most accurate method for determining the presence and quantity of various type of Hemoglobins.
• The Bio Rad Variant II hemoglobin testing system is a fully automated HPLC system which is used to separate and determine specific
hemoglobin in whole blood. This method is used to screen for abnormal hemoglobins.
• Please take into consideration any recent blood transfusion (within 3 months) that has been given to the patient, which may alter the results.
• In case any abnormal hemoglobin is identified on the HPLC screen, Family study and genetic analysis is recommended for confirmation of
diagnosis.

Page 3 of 5

SIN No:A0282147
 Patient Name : SUDHA RANI Barcode : A0282147
Age/Gender : 52Y 0M 0D /Female Sample Collected On : 05/Dec/2024 02:53PM
Order Id : 12266358238 Sample Received On : 06/Dec/2024 09:09AM
Referred By : Self Report Generated On : 06/Dec/2024 09:45AM
Customer Since : 05/Dec/2024 Sample Temperature : Maintained
Sample Type : Serum Report Status : Final Report

DEPARTMENT OF IMMUNOLOGY

Test Name Value Unit Bio. Ref Interval

Folate (Folic Acid)

FOLIC ACID / FOLATE - SERUM 15.95 ng/ml >5.38
Method: CLIA
Machine: Siemens Atellica IM1300

Folates are compounds of pteroylglutamic acid (PGA) that function as coenzymes in

metabolic reactions involving the transfer of single-carbon units from a donor to a
recipient compound. Folate, with vitamin B12, is essential for DNA synthesis, which is
required for normal red blood cell maturation.
Low folate intake, malabsorption as a result of gastrointestinal diseases, pregnancy, and
drugs such as phenytoin are causes of folate deficiency. Folate deficiency is also
associated with chronic alcoholism.
Folate and vitamin B12 deficiency impair DNA synthesis, causing macrocytic anemias.
These anemias are characterized by abnormal maturation of red blood cell precursors in
the bone marrow, the presence of megaloblasts, and decreased red blood cell survival.
Since both folate and vitamin B12 deficiency can cause macrocytic anemia, appropriate
treatment depends on the differential diagnosis of the deficiency. Serum folate
measurement provides an early index of folate status. However, folate is much more
concentrated in red blood cells than in serum so the red blood cell folate measurement more closely reflects tissue stores. Red blood cell folate
concentration is considered the
most reliable indicator of folate status.

Increased in

Blind loop syndrome

Vegetarian diet
Distal and small bowel disease
Pernicious anemia

Decreased in

Alcoholism, Liver disease

Malnutrition
Scurvy
B12 deficiency
Celiac disease

Page 4 of 5

SIN No:A0282147
 Patient Name : SUDHA RANI Barcode : A0282147
Age/Gender : 52Y 0M 0D /Female Sample Collected On : 05/Dec/2024 02:53PM
Order Id : 12266358238 Sample Received On : 06/Dec/2024 09:09AM
Referred By : Self Report Generated On : 06/Dec/2024 09:45AM
Customer Since : 05/Dec/2024 Sample Temperature : Maintained
Sample Type : Serum Report Status : Final Report

DEPARTMENT OF IMMUNOLOGY

Test Name Value Unit Bio. Ref Interval

Sideroblastic anemia

Page 5 of 5

SIN No:A0282147
Bio-Rad CDM System PATIENT REPORT
VII Inst. #2. SN-15999 V2_BThal

Patient Data Analysis Data

Sample ID: A0282147 Analysis Performed: 06/12/2024 12:44:36
Patient ID: Injection Number: 13173
Name: Run Number: 538
Physician: Rack ID:
Sex: Tube Number: 8
DOB: Report Generated: 06/12/2024 14:06:09
Comments: Operator ID:

Calibrated Retention Peak

Peak Name Area % Area % Time (min) Area
Unknown --- 0.1 1.00 1101
F 0.3 --- 1.08 6030
Unknown --- 1.6 1.19 31429
P2 --- 4.9 1.31 94698
P3 --- 4.8 1.73 93569
Ao --- 85.8 2.38 1662215
A2 2.4 --- 3.65 48465

Total Area: 1,937,508

F Concentration = 0.3 %
A2 Concentration = 2.4 %

Analysis comments:

45.0

37.5

30.0

22.5
%

1.31

3.65
1.73

15.0
1.19
1.08
1.00

2.38

7.5
A2 -
-
-
-F -

0.0
-

0 1 2 3 4 5 6
Time (min.)